Literature DB >> 33068021

Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.

Amandeep Godara1,2, Denis Toskic1, Jack Albanese1, Benjamin Rosenthal1, Nauman S Siddiqui2, Adin Kugelmass1, Ping Zhou1, Teresa Fogaren1,2, Cindy Varga1,2, Heather J Landau3, Raymond L Comenzo1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33068021      PMCID： PMC8436337          DOI： 10.1002/ajh.26025

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

1.  Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.

Authors:  Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; David Dingli; Francis K Buadi; Martha Grogan; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Wilson Gonsalves; Rahma Warsame; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Blood       Date:  2017-01-26       Impact factor: 22.113

Review 2.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

Review 3.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

4.  A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Authors:  Richa Manwani; Oliver Cohen; Faye Sharpley; Shameem Mahmood; Sajitha Sachchithanantham; Darren Foard; Helen J Lachmann; Cristina Quarta; Marianna Fontana; Julian D Gillmore; Carol Whelan; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

5.  Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.

Authors:  B Paiva; M Pérez-Andrés; M-B Vídriales; J Almeida; N de las Heras; M-V Mateos; L López-Corral; N C Gutiérrez; J Blanco; A Oriol; M T Hernández; F de Arriba; A G de Coca; M-J Terol; J de la Rubia; Y González; A Martín; A Sureda; M Schmidt-Hieber; A Schmitz; H E Johnsen; J-J Lahuerta; J Bladé; J F San-Miguel; A Orfao
Journal:  Leukemia       Date:  2011-01-21       Impact factor: 11.528

6.  AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Authors:  Tobias Dittrich; Tilmann Bochtler; Christoph Kimmich; Natalia Becker; Anna Jauch; Hartmut Goldschmidt; Anthony D Ho; Ute Hegenbart; Stefan O Schönland
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

7.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

8.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

9.  Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Authors:  R L Comenzo; E Vosburgh; R W Simms; P Bergethon; D Sarnacki; K Finn; S Dubrey; D V Faller; D G Wright; R H Falk; M Skinner
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Revisiting complete response in light chain amyloidosis.

Authors:  Surbhi Sidana; Angela Dispenzieri; David L Murray; Ronald S Go; Francis K Buadi; Martha Q Lacy; Wilson I Gonsalves; David Dingli; Rahma Warsame; Taxiarchis Kourelis; Eli Muchtar; Suzanne R Hayman; Prashant Kapoor; Robert A Kyle; Nelson Leung; S Vincent Rajkumar; Morie A Gertz; Shaji K Kumar
Journal:  Leukemia       Date:  2019-11-26       Impact factor: 11.528
  10 in total
  1 in total

Review 1.  Cardiac Amyloidosis.

Authors:  Morie A Gertz
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.